Scarica l'app Stockscreener
26.55
2.89%
-0.79
Dopo l'orario di chiusura:
26.55
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$27.34
Aprire:
$27.53
Volume 24 ore:
773.74K
Relative Volume:
0.64
Capitalizzazione di mercato:
$1.76B
Reddito:
$5.79M
Utile/perdita netta:
$-199.61M
Rapporto P/E:
-8.8206
EPS:
-3.01
Flusso di cassa netto:
$-188.48M
1 W Prestazione:
-3.59%
1M Prestazione:
+8.01%
6M Prestazione:
+49.16%
1 anno Prestazione:
-10.67%
Intervallo 1D:
$26.17
$27.89
Intervallo di 1 settimana:
$24.50
$27.89
Portata 52W:
$14.40
$29.93
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Nome
Celldex Therapeutics Inc
Settore
Industria
Telefono
908-200-7500
Indirizzo
53 FRONTAGE ROAD, HAMPTON
Confronta CLDX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
26.55 | 1.76B | 5.79M | -199.61M | -188.48M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-28 | Iniziato | Canaccord Genuity | Buy |
| 2025-03-20 | Iniziato | Morgan Stanley | Overweight |
| 2025-02-13 | Iniziato | UBS | Buy |
| 2024-10-07 | Iniziato | Citigroup | Buy |
| 2024-09-30 | Iniziato | Goldman | Neutral |
| 2024-09-27 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | Iniziato | Stifel | Buy |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2023-12-20 | Iniziato | TD Cowen | Outperform |
| 2023-11-10 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | Iniziato | Wells Fargo | Underweight |
| 2021-09-17 | Iniziato | Jefferies | Buy |
| 2021-09-10 | Iniziato | SVB Leerink | Outperform |
| 2021-07-22 | Iniziato | Guggenheim | Buy |
| 2020-02-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-08-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-07 | Iniziato | Aegis Capital | Buy |
| 2016-03-08 | Downgrade | Jefferies | Buy → Hold |
| 2016-03-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2016-03-07 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2016-03-01 | Iniziato | H.C. Wainwright | Buy |
| 2015-08-11 | Reiterato | Brean Capital | Buy |
| 2015-08-11 | Reiterato | Oppenheimer | Outperform |
| 2015-08-11 | Reiterato | ROTH Capital | Buy |
| 2015-06-02 | Reiterato | WBB Securities | Strong Buy |
| 2014-11-17 | Reiterato | ROTH Capital | Buy |
| 2014-03-04 | Reiterato | Oppenheimer | Outperform |
| 2013-07-08 | Reiterato | Cantor Fitzgerald | Buy |
| 2013-03-08 | Reiterato | Cantor Fitzgerald | Buy |
| 2013-02-26 | Reiterato | Oppenheimer | Outperform |
| 2013-01-10 | Reiterato | Cantor Fitzgerald | Buy |
| 2012-10-02 | Reiterato | Oppenheimer | Outperform |
| 2012-09-14 | Reiterato | Cantor Fitzgerald | Buy |
Mostra tutto
Celldex Therapeutics Inc Borsa (CLDX) Ultime notizie
Best data tools to analyze Celldex Therapeutics Inc. stockPortfolio Update Summary & Stepwise Entry/Exit Trade Alerts - newser.com
Chart overlay techniques for tracking Celldex Therapeutics Inc.Trade Analysis Summary & AI Optimized Trade Strategies - newser.com
Real time alert setup for Celldex Therapeutics Inc. performanceWall Street Watch & Reliable Intraday Trade Alerts - newser.com
Why analysts remain bullish on Celldex Therapeutics Inc. stockIPO Watch & Free Technical Pattern Based Buy Signals - newser.com
Published on: 2025-10-14 10:43:50 - newser.com
Is it too late to sell Celldex Therapeutics Inc.Portfolio Performance Report & Pattern Based Trade Signal System - newser.com
Barclays Initiates Coverage of Celldex Therapeutics (CLDX) with Underweight Recommendation - Nasdaq
How Investors Are Reacting To Celldex Therapeutics (CLDX) After Barclays Shines Spotlight on Biotech Innovation - Sahm
Celldex Therapeutics: Caution Warranted After Big Rebound (Rating Downgrade) (NASDAQ:CLDX) - Seeking Alpha
Barclays initiates Celldex Therapeutics stock with Underweight rating By Investing.com - Investing.com Canada
Published on: 2025-10-13 08:38:10 - newser.com
Barclays Initiates Celldex Therapeutics at Underweight With $25 Price Target - MarketScreener
Published on: 2025-10-13 01:55:53 - newser.com
Is Celldex Therapeutics Inc. stock a bargain at current levelsJuly 2025 Breakouts & Detailed Earnings Play Strategies - newser.com
Is Celldex Therapeutics Inc. reversing from oversold territoryPortfolio Gains Report & Daily Technical Stock Forecast Reports - newser.com
Chronic Spontaneous Urticaria Pipeline Drugs Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight - Barchart.com
How interest rate cuts could boost Celldex Therapeutics Inc. stockPortfolio Value Report & Daily Stock Momentum Reports - newser.com
Celldex Therapeutics (NASDAQ:CLDX) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
Urticaria Pipeline Drugs Insights Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight - Barchart.com
Celldex Bets Big On Its Allergy Pipeline Breakthroughs - Finimize
Analyzing Celldex Therapeutics Inc. with risk reward ratio charts2025 Market Outlook & Weekly High Conviction Ideas - newser.com
Is Celldex Therapeutics Inc. still worth holding after the dip2025 Breakouts & Breakdowns & Growth Oriented Trading Recommendations - newser.com
When is the best time to exit Celldex Therapeutics Inc.2025 Fundamental Recap & Weekly High Momentum Picks - newser.com
Will Celldex Therapeutics Inc. rebound enough to break evenMarket Risk Report & Reliable Intraday Trade Alerts - newser.com
Celldex Therapeutics Experiences Evaluation Revision Amidst Market Dynamics and Performance Fluctuations - Markets Mojo
Celldex Therapeutics (NASDAQ:CLDX) Share Price Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
How moving averages guide Celldex Therapeutics Inc. trading2025 Institutional Moves & Consistent Growth Stock Picks - newser.com
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above 200-Day Moving Average – Here’s What Happened - Defense World
Analysis: Positioning to Benefit within Applied Materials, MRC Global, Meritor, Celldex Therapeutics, Quaker Chemical, and Cu... - ADVFN
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above 200-Day Moving AverageHere's What Happened - MarketBeat
One Celldex Therapeutics Insider Raised Stake By 40% In Previous Year - 富途牛牛
Celldex Therapeutics Inc Azioni (CLDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Celldex Therapeutics Inc Azioni (CLDX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Marucci Anthony S | PRESIDENT & CEO |
Nov 11 '24 |
Buy |
26.82 |
11,500 |
308,430 |
40,284 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):